A citation-based method for searching scientific literature

Alice T Shaw, Benjamin J Solomon, Rita Chiari, Gregory J Riely, Benjamin Besse, Ross A Soo, Steven Kao, Chia-Chi Lin, Todd M Bauer, Jill S Clancy, Holger Thurm, Jean-Francois Martini, Gerson Peltz, Antonello Abbattista, Sherry Li, Sai-Hong Ignatius Ou. Lancet Oncol 2019
Times Cited: 135



Kristin Bergethon, Alice T Shaw, Sai-Hong Ignatius Ou, Ryohei Katayama, Christine M Lovly, Nerina T McDonald, Pierre P Massion, Christina Siwak-Tapp, Adriana Gonzalez, Rong Fang, Eugene J Mark, Julie M Batten, Haiquan Chen, Keith D Wilner, Eunice L Kwak, Jeffrey W Clark, David P Carbone, Hongbin Ji, Jeffrey A Engelman, Mari Mino-Kenudson, William Pao, A John Iafrate. J Clin Oncol 2012
Times Cited: 1053




List of shared articles



Times cited

Complications following novel therapies for non-small cell lung cancer.
Marcus Skribek, Konstantinos Rounis, Georgios Tsakonas, Simon Ekman. J Intern Med 2022
0

Safety and activity of WX-0593 (Iruplinalkib) in patients with ALK- or ROS1-rearranged advanced non-small cell lung cancer: a phase 1 dose-escalation and dose-expansion trial.
Yuankai Shi, Jian Fang, Xuezhi Hao, Shucai Zhang, Yunpeng Liu, Lin Wang, Jianhua Chen, Yi Hu, Xiaosheng Hang, Juan Li,[...]. Signal Transduct Target Ther 2022
1

ROS-1 Fusions in Non-Small-Cell Lung Cancer: Evidence to Date.
Sébastien Gendarme, Olivier Bylicki, Christos Chouaid, Florian Guisier. Curr Oncol 2022
0

Lorlatinib for advanced ROS1+ non-small-cell lung cancer: results of the IFCT-1803 LORLATU study.
N Girard, S Galland-Girodet, V Avrillon, B Besse, M Duruisseaux, J Cadranel, J Otto, A Prevost, B Roch, J Bennouna,[...]. ESMO Open 2022
1


Biomarker guided treatment in oncogene-driven advanced non-small cell lung cancer in older adults: A Young International Society of Geriatric Oncology Report.
Konstantinos Christofyllakis, Ana Raquel Monteiro, Onur Cetin, Igor Age Kos, Alastair Greystoke, Andrea Luciani. J Geriatr Oncol 2022
0

Strengths and pitfalls of brigatinib in non-small cell lung cancer patients' management.
Fabrizio Tabbò, Marco DE Filippis, Francesca Jacobs, Silvia Novello. Minerva Med 2022
0

ROS1-positive non-small cell lung cancer (NSCLC): biology, diagnostics, therapeutics and resistance.
Zhi-Qiong Yu, Meng Wang, Wen Zhou, Meng-Xia Mao, Yuan-Yuan Chen, Na Li, Xiao-Chun Peng, Jun Cai, Zhi-Qiang Cai. J Drug Target 2022
0

Long-Term Efficacy and Safety of Entrectinib in ROS1 Fusion-Positive NSCLC.
Alexander Drilon, Chao-Hua Chiu, Yun Fan, Byoung Chul Cho, Shun Lu, Myung-Ju Ahn, Matthew G Krebs, Stephen V Liu, Thomas John, Gregory A Otterson,[...]. JTO Clin Res Rep 2022
0

Brain Metastases Management in Oncogene-Addicted Non-Small Cell Lung Cancer in the Targeted Therapies Era.
Elisa De Carlo, Elisa Bertoli, Alessandro Del Conte, Brigida Stanzione, Eleonora Berto, Alberto Revelant, Michele Spina, Alessandra Bearz. Int J Mol Sci 2022
0

Targeting molecular alterations in non-small-cell lung cancer: what's next?
Rafael López-Castro, Tania García-Peña, Xabier Mielgo-Rubio, Mariona Riudavets, Cristina Teixidó, Noelia Vilariño, Felipe Couñago, Laura Mezquita. Per Med 2022
0

Pharmacophore-based designing of putative ROS-1 targeting agents for NSCLC.
Disha Pathak, Shalki Choudhary, Pankaj Kumar Singh, Manjinder Singh, Navriti Chadha, Om Silakari. Mol Divers 2021
3

ROS1-dependent cancers - biology, diagnostics and therapeutics.
Alexander Drilon, Chelsea Jenkins, Sudarshan Iyer, Adam Schoenfeld, Clare Keddy, Monika A Davare. Nat Rev Clin Oncol 2021
43


Short-term response to immune-chemotherapy and immune features of a ceritinib-resistant patient with ROS1-rearranged lung adenocarcinoma.
Dongsheng Yue, Juanjuan Qian, Zhipeng Chen, Bin Zhang, Peng Chen, Lei Zhang, Jingjing Li, Henghui Zhang, Changli Wang. J Immunother Cancer 2021
1

Systemic Therapy for Mutation-Driven NSCLC.
Lova Sun, Melina E Marmarelis, Corey J Langer. Semin Radiat Oncol 2021
1

Lorlatinib in pretreated ALK- or ROS1-positive lung cancer and impact of TP53 co-mutations: results from the German early access program.
Nikolaj Frost, Petros Christopoulos, Diego Kauffmann-Guerrero, Jan Stratmann, Richard Riedel, Monica Schaefer, Jürgen Alt, Sylvia Gütz, Daniel C Christoph, Eckart Laack,[...]. Ther Adv Med Oncol 2021
10

Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic ROS1 Fusion-Positive Non-Small-Cell Lung Cancer.
Rafal Dziadziuszko, Matthew G Krebs, Filippo De Braud, Salvatore Siena, Alexander Drilon, Robert C Doebele, Manish R Patel, Byoung Chul Cho, Stephen V Liu, Myung-Ju Ahn,[...]. J Clin Oncol 2021
24


Uncommon targets in non-small cell lung cancer: Everyone wants a slice of cake.
Alessandro De Toma, Giuseppe Lo Russo, Diego Signorelli, Filippo Pagani, Giovanni Randon, Giulia Galli, Arsela Prelaj, Roberto Ferrara, Claudia Proto, Monica Ganzinelli,[...]. Crit Rev Oncol Hematol 2021
3

Lorlatinib Exposure-Response Analyses for Safety and Efficacy in a Phase I/II Trial to Support Benefit-Risk Assessment in Non-Small Cell Lung Cancer.
Joseph Chen, Ana Ruiz-Garcia, Leonard P James, Gerson Peltz, Holger Thurm, Jill Clancy, Jennifer Hibma. Clin Pharmacol Ther 2021
6

Treatment of Rare Mutations in Patients with Lung Cancer.
Tarek Taha, Rasha Khoury, Ronen Brenner, Haitam Nasrallah, Irena Shofaniyeh, Samih Yousef, Abed Agbarya. Biomedicines 2021
2

Monitoring and Managing Lorlatinib Adverse Events in the Portuguese Clinical Setting: A Position Paper.
Fernando Barata, Carlos Aguiar, Tiago Reis Marques, José Bravo Marques, Venceslau Hespanhol. Drug Saf 2021
1

Lung cancer.
Alesha A Thai, Benjamin J Solomon, Lecia V Sequist, Justin F Gainor, Rebecca S Heist. Lancet 2021
112


First-Line Treatment of Metastatic Non-Small Cell Lung Cancer in the Elderly.
Tania Losanno, Cesare Gridelli. Curr Oncol Rep 2021
0

Response to Immune Checkpoint Inhibition as Monotherapy or in Combination With Chemotherapy in Metastatic ROS1-Rearranged Lung Cancers.
Noura J Choudhury, Jaime L Schneider, Tejas Patil, Viola W Zhu, Debra A Goldman, Soo-Ryum Yang, Christina J Falcon, Andrew Do, Yunan Nie, Andrew J Plodkowski,[...]. JTO Clin Res Rep 2021
3

Diagnostic, Predictive, and Prognostic Biomarkers in Non-Small Cell Lung Cancer (NSCLC) Management.
Maja Šutić, Ana Vukić, Jurica Baranašić, Asta Försti, Feđa Džubur, Miroslav Samaržija, Marko Jakopović, Luka Brčić, Jelena Knežević. J Pers Med 2021
4

Recent advances in lung cancer genomics: Application in targeted therapy.
Neha Pathak, Sindhura Chitikela, Prabhat Singh Malik. Adv Genet 2021
1

Deepening the Knowledge of ROS1 Rearrangements in Non-Small Cell Lung Cancer: Diagnosis, Treatment, Resistance and Concomitant Alterations.
Giorgia Guaitoli, Federica Bertolini, Stefania Bettelli, Samantha Manfredini, Michela Maur, Lucia Trudu, Beatrice Aramini, Valentina Masciale, Giulia Grisendi, Massimo Dominici,[...]. Int J Mol Sci 2021
3


A novel ROS1 G2032 K missense mutation mediates lorlatinib resistance in a patient with ROS1-rearranged lung adenocarcinoma but responds to nab-paclitaxel plus pembrolizumab.
Yuling Zhou, Wenjuan Jiang, Liang Zeng, Jinye Mi, Lianxi Song, Analyn Lizaso, Xinru Mao, Nong Yang, Yongchang Zhang. Lung Cancer 2020
6

Entrectinib for the treatment of metastatic NSCLC: safety and efficacy.
Andrea Sartore-Bianchi, Elio Gregory Pizzutilo, Giovanna Marrapese, Federica Tosi, Giulio Cerea, Salvatore Siena. Expert Rev Anticancer Ther 2020
10

Oncogene-Addicted Non-Small-Cell Lung Cancer: Treatment Opportunities and Future Perspectives.
Miriam Grazia Ferrara, Vincenzo Di Noia, Ettore D'Argento, Emanuele Vita, Paola Damiano, Antonella Cannella, Marta Ribelli, Sara Pilotto, Michele Milella, Giampaolo Tortora,[...]. Cancers (Basel) 2020
30

Treatment Patterns and Clinical Outcomes Among Patients With ROS1-rearranged Non-small-cell Lung Cancer Progressing on Crizotinib.
Andrea De Giglio, Giuseppe Lamberti, Francesco Facchinetti, Carlo Genova, Elisa Andrini, Maria Giovanna Dal Bello, Marcello Tiseo, Giulio Metro, Rita Chiari, Biagio Ricciuti. Clin Lung Cancer 2020
2

Clinical activity of brigatinib in ROS1-rearranged non-small cell lung cancer.
E Dudnik, A Agbarya, R Grinberg, A Cyjon, J Bar, M Moskovitz, N Peled. Clin Transl Oncol 2020
4